URGN UroGen Pharma Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1668243 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY159.3%
TTM net income YoY60.1%
TTM EPS YoY—
Revenue 3-yr CAGR47.9%
Net income 3-yr CAGR—
Margins
Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
FCF margin-52.8%
EBITDA margin-12.2%
Returns
ROE—
ROA-28.8%
ROIC (approx.)—
Asset turnover1.10x
Leverage & solvency
Liabilities / assets146.1%
Debt / equity—
Current ratio3.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.01x
Accruals ratio28.9%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $109.79M | $90.40M |
| Cost of revenue | $12.45M | $8.88M |
| Gross profit | $97.34M | $81.52M |
| R&D expense | $67.11M | $57.15M |
| SG&A expense | $155.10M | $121.15M |
| Operating income | -$124.86M | -$96.78M |
| Pretax income | -$153.42M | -$124.04M |
| Income tax | $78,000 | $2.83M |
| Net income | -$153.49M | -$126.87M |
| EBITDA | -$124.56M | -$96.45M |
| EPS (basic) | -3.19 | -2.96 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $110.75M | $171.99M |
| Short-term investments | $9.71M | $110.67M |
| Receivables | $33.08M | $20.30M |
| Inventory | $16.46M | $9.23M |
| Current assets | $186.02M | $276.13M |
| PP&E, net | $637,000 | $655,000 |
| Total assets | $200.46M | $285.71M |
| Current liabilities | $46.42M | $45.95M |
| Long-term debt | $122.21M | $121.73M |
| Total debt | $122.21M | $121.73M |
| Total liabilities | $305.93M | $294.51M |
| Shareholders' equity | -$105.47M | -$8.80M |
| Net debt | $11.46M | -$50.25M |
| Shares outstanding | 48.35M | 42.23M |
| Cash flow statement | ||
| Operating cash flow | -$162.44M | -$96.77M |
| Capital expenditure | $289,000 | $295,000 |
| Free cash flow | -$162.73M | -$97.06M |
| Investing cash flow | $61.56M | -$20.61M |
| Financing cash flow | $39.92M | $194.62M |
| Depreciation & amortization | $307,000 | $329,000 |
| Stock-based compensation | $11.96M | $13.11M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.